放射肿瘤学质量改进干预的国际系统综述
该系统综述检索2000至2024年MEDLINE和EMBASE,纳入26项放射肿瘤学质量改进干预研究,多数来自美国(13项)和欧洲(7项),仅2项为国家层面。所有干预均改善了流程或患者相关结局指标,但资金报告率仅42%,国家层面研究稀缺。
要点
- 纳入26项质量改进干预研究,多数来自美国(13项)和欧洲(7项),仅2项为国家层面。
- 最常评估的环节为减少等待时间或提高放疗利用率(15项),其次为减少靶区勾画变异(5项)和处理放疗期间或之后症状(6项)。
- 所有26项研究的质量改进干预均成功改善了某项流程或患者相关结局指标。
核心结论
- 尽管癌症研发投入巨大,但关于如何提升放射肿瘤学照护质量的信息仍很稀缺。
- 许多国家已有国家癌症审计和登记,但质量改进干预研究大多在美国开展。
- 这一状况凸显需要更全面、资金充足的研究,并改善临床医生培训以开展高质量改进活动和 Research。
研究设计与样本
- 系统检索MEDLINE和EMBASE,纳入2000至2024年间放射肿瘤学质量改进干预研究。
- 纳入标准为研究需识别质量改进干预对流程指标或患者相关结局的定量或定性影响。
- 共纳入26篇论文,采用叙述性综合汇总结果,并使用质量改进最低质量标准集(QI-MQCS)进行评价。
主要发现
- 多数研究在美国开展(n=13)和欧洲(n=7),仅2项研究在国家层面开展。
- 10项研究覆盖所有肿瘤类型,6项专门聚焦头颈癌,前列腺癌和鼻咽癌各2项,肺癌、宫颈癌、直肠癌和乳腺癌各1项。
- 最常评估的照护环节为减少等待时间或按指南提高放疗利用率(n=15),其次为减少放疗靶区勾画变异(n=5)和处理放疗期间或之后症状(n=6)。
- 仅42%的研究报告了资金,最常见的资金来源为国家、政府或联邦(n=6)。
- 所有26项研究中的质量改进干预均成功,均改善了某项流程或患者相关结局指标;研究按QI-MQCS标准评分为10至15分(满分16分)。
关键数值与推荐
- 26项研究按QI-MQCS标准评分为10至15分(满分16分)。
- 仅42%的研究报告资金,最常见资金来源为国家、政府或联邦(n=6)。
局限性
- 原文指出尽管癌症研发投入巨大,但关于如何提升放射肿瘤学照护质量的信息仍很稀缺。
- 原文指出质量改进干预研究大多在美国开展,国家层面研究仅2项。
- 原文强调需要更全面、资金充足的研究并改善临床医生培训以开展高质量改进活动和 Research。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
National cancer audits and registers have highlighted significant national and international variation in patient care and outcomes. Quality Improvement (QI) is mandated in radiation oncology but the interventions designed to support QI in this field remain poorly understood. This paper seeks to assess the types of QI interventions in radiation oncology, the QI evaluation design and their impact on process of care measures and patient-related outcomes. MEDLINE and EMBASE were searched systematically for studies of QI interventions in radiation oncology between 2000 and 2024. The studies needed to identify the quantitative or qualitative impact of the QI intervention on process of care measures or patient-related outcomes. Study results were summarised using narrative synthesis and appraised using the Quality Improvement Minimum Quality Criteria Set (QI-MQCS). 26 papers were included in the analysis. The majority of studies were conducted in the USA (n = 13) and in Europe (n = 7), with only two studies conducted at a national level. Ten studies covered all tumour types, with six specifically focusing on head and neck cancers, two each on prostate and nasopharyngeal cancers, and one study each examining lung, cervical, rectal, and breast cancers. The aspects of care evaluated most frequently were those relating to reducing waiting times or increasing utilisation of radiotherapy as per guidelines (n = 15), followed by those seeking to reduce radiotherapy contouring variability (n = 5) and those involving the management of symptoms during or after radiotherapy treatment (n = 6). Only 42 % of studies reported funding, with the most frequent funding source being national, government or federal (n = 6). All QI interventions across the 26 studies were successful as they resulted in an improvement in a process or patient-related outcome measure. The studies scored between 10 and 15 out of 16, according to the QI-MQCS criteria. Despite substantial investments in cancer research and development, there is a scarcity of information on how to enhance the quality of care in radiation oncology. While there are examples of national cancer audits and registers in a number of countries, much of the research in QI interventions is being conducted in the USA. This situation underscores the need for more comprehensive, well-funded studies and improved training for clinicians to conduct high-quality improvement activities and research. There should be a greater emphasis on the substantial gains that can be achieved by improving existing care in terms of access and outcomes, rather than solely focusing on innovation.
引用
- Dodkins J, Zachou G, Rashid A, et al. Improving performance in radiation oncology: An international systematic review of quality improvement interventions. Radiother Oncol. 2025. PMID: 39986541. doi:10.1016/j.radonc.2025.110798
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。